海角社区

Director of the Blood and Marrow Transplant Center, Roswell Park Cancer Institute Areas of expertise: Bone marrow transplant, leukemia, lymphoma, multiple myeloma, blood cancer, hematologic oncology

Modupe Idowu, MD, treats patients with sickle cell anemia, myeloproliferative neoplasm, thrombotic disorders, and hematologic malignancy including lymphoproliferative disorders, plasma cell dyscracias, and leukemias. Her research interests in clinical and translational investigations involve sickle cell anemia and thrombotic disorders. She is the medical director of the UT Physicians Comprehensive Sickle Cell Center.

Dr. Francine Foss, Professor of Medicine in the Section of Medical Oncology at Yale Cancer Center, is an internationally recognized clinician and clinical researcher with expertise in adult lymphomas and in stem cell transplantation. She has developed and tested therapies that have been used to treat thousands of cancer patients, and her research has substantially impacted the field of stem cell research, benefiting patients at Yale and around the world. Dr. Foss has brought a nationally established clinical trials program to Yale Cancer Center. In her previous position at Tufts New England Medical Center in Boston, she designed, initiated, and directed multi-center national clinical trials which led to FDA approval of several novel therapies for lymphomas. One of these, Interleukin-2- Diphtheria toxin fusion protein, was the first FDA-approved fusion protein biologic drug and the first drug to be FDA approved for the treatment of T-cell lymphoma. In her laboratory work, she investigated and elucidated the mechanism by which extracorporeal photopheresis modulated antigen presenting cells, leading to a reduction in graft-vs-host disease in patients undergoing allogeneic stem cell transplant. These findings led to the initiation of two National Cancer Institute-sponsored trials to confirm these results in patients with lymphoma and myelodysplastic syndrome. Dr. Foss is a member of the Stem Cell Therapy clinical program at Smilow Cancer Hospital.

Dr. Foss is a world expert in T cell Lymphomas. She has pioneered several novel therapies for T cell lymphomas and has been a leader in many national studies. She developed and initiated the first national registry for T cell lymphomas in the United States and is a founder and co-chairman of the T CELL Forum, the preeminent international T cell lymphoma research meeting. She is a co-founder of the United States Cutaneous Lymphoma Consortium and currently serves as its President. She has been a Director of the international T-cell Project to research treatment and biology of T-cell lymphomas and serves on the NCCN panel of experts for T-cell lymphomas. As a translational researcher in T cell Lymphomas, she currently is collaborating with a number of laboratories and scientists at Yale to identify molecular targets in T Cell Lymphoma and recently was awarded a grant through the PITCH program for the state of Connecticut to develop a promising small molecule therapeutic for a rare form of lymphoma. Dr. Foss currently leads the multi-disciplinary T-cell Lymphoma clinical team at the Smilow Cancer Center and co-directs the Cutaneous Lymphoma Program at Yale with Dr. Michael Girardi. Her clinical practice at Smilow Cancer Hospital attracts patients from around the world.

George Goshua, MD, MSc is an Assistant Professor of Medicine (Hematology) in the Clinician-Scientist Track. He is a Yale-trained, board-certified internist and hematologist, with methodological training in risk and decision science from the Harvard T.H. Chan School of Public Health. Dr. Goshua is the PI of the first quantitative decision analytic modeling laboratory in hematology-oncology in the United States (Goshua Lab). His clinical expertise is in the care of adults with rare hematologic disorders, with a particular focus in immunohematology and thrombosis. His laboratory research employs quantitative decision analytic modeling methods to #1 fill gaps in clinical guidelines, #2 impact health resource allocation and/or #3 inform health policy decisions. This body of original science has been published in journals that include the Annals of Internal Medicine, Blood (inclusive of a #1 globally trending manuscript), The Lancet Haematology (the journal's #1 most cited original research), The Lancet Regional Health, Blood Advances, American Journal of Hematology (2021 AJH Young Investigator Award, 2022 AJH YIA Finalist), Science Immunology, Chest, and Clinical Infectious Diseases. Beyond research recognitions awarded by the leading hematology societies, Dr. Goshua's invited service at the interface of decision science and clinical medicine includes the 1. American Society of Hematology Patient Decision Aid Steering Group, 2. Institute for Clinical and Economic Review's Independent Appraisal Committee, and 3. Editorial Board at the Annals of Internal Medicine, with an expert focus in health economics.